Recruiting
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
ClinicalTrials.gov IDNCT06984250
PhaseNot Applicable
Enrollment315
SponsorNational Taiwan University Hospital
Age20 Years – 85 Years
SexFEMALE
Conditions studied
Early Breast Cancer, Ductal Breast Carcinoma In Situ
About this study
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
Interventions
- Radiation: Hypofractionated Radiation Therapy — Hypofractionated breast radiotherapy (HFRT) with hybrid techniques combining field-in-field intensity-modulated RT (FIF-IMRT) to the whole breast with inverse-IMRT for concomitant boost
Primary outcomes
- Ipsilateral breast tumor recurrence (From enrollment to the end of treatment at 2 years)
Eligibility information
Inclusion Criteria:
* Female patients with histologically confirmed early-stage breast cancer (T1-2 and N0-1) or ductal carcinoma in situ (DCIS).
* Patients undergoing breast-conserving surgery
* Age ≥ 20 years
* Karnofsky Performance Status (KPS) ≥70%
* Life expectancy ≥ 5 years
* Adequate renal and hepatic function
Exclusion Criteria:
* Pregnant patients
* Patients requiring re-irradiation of the thoracic region
Study locations
- National Taiwan University Hospital, Taipei, Taiwan 100 Taiwan
- National Taiwan University Hospital Yunlin Branch, Taipei, 632 Taiwan
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-09.